Republished: Sensitive troponin assays

Postgraduate Medical Journal

Volumn 88, Issue 1040, 2012, Pages 348-352

  Collinson, Paul O ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN;

ACUTE CORONARY SYNDROME; ARTICLE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LABORATORY; PATHOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS;

EID: 84861141104     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj-2011-200164rep     Document Type: Article

References (53)

1. Stubbs P, Collinson P, Moseley D, et al. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. [see Comments]. BMJ 1996;313:262-4.
2. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. [see Comments]. N Engl J Med 1992;327:146-50.
3. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.
4. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997;29:43-8.
5. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. [In process citation]. J Am Coll Cardiol 2000;36:1812-17.
6. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
7. Anon. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-15.
8. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-12.
9. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-660.
10. Clyne CA, Medeiros LJ, Marton KI. The prognostic significance of immunoradiometric CK-MB assay (IRMA) diagnosis of myocardial infarction in patients with low total CK and elevated MB isoenzymes. Am Heart J 1989;118:901-6.
11. Ravkilde J, Hansen AB, Hørder M, et al. Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2.5-year follow-up study in 156 consecutive patients. Cardiology 1992;80:143-51.
12. Missov E, Calzolari C, Davy JM, et al. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537-41.
13. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
14. Wu AH, Apple FS, Gibler WB, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
15. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
16. Anon. Myocardial infarction redefinedea consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
17. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-9.
18. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
19. Tonks DB. A study of the accuracy and precision of clinical chemistry determinations in 170 Canadian laboratories. Clin Chem 1963;9:217-33.
20. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996;42:140-5.
21. Fraser CG, Petersen PH. Desirable standards for laboratory tests if they are to fulfill medical needs. Clin Chem 1993;39:1447-53.
22. Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005;51:2198-200.
23. Collinson PO, Clifford-Mobley O, Gaze D, et al. Assay imprecision and 99thpercentile reference value of a high-sensitivity cardiac troponin I assay. Clin Chem 2009;55:1433-4.
24. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009;55:1303-6.
25. Jaffe AS, Apple FS, Morrow DA, et al. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/ World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem 2010;56:941-3.
26. Collinson PO, Gaze DC, Morris F, et al. Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Ann Clin Biochem 2006;43:273-80.
27. Eggers KM, Oldgren J, Nordenskjöld A, et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004;148:574-81.
28. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
29. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
30. Collinson PO. We don't need another heroeis there a role for ischemia biomarkers in patients with chest pain? Clin Chim Acta 2009;404:87-8.
31. Rao AC, Collinson PO, Rose AJ, et al. Prospective evaluation of the role of routine cardiac troponin T measurement to identify left ventricular ejection fraction <40% after first myocardial infarction. Heart 2003;89:559-60.
32. Panteghini M, Bonetti G, Pagani F, et al. Measurement of troponin I 48 h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction. Clin Chem Lab Med 2005;43:848-54.
33. Hallén J, Jensen JK, Fagerland MW, et al. Cardiac troponin I for the prediction of functional recovery and left ventricular remodelling following primary percutaneous coronary intervention for ST-elevation myocardial infarction. Heart 2010;96:1892-7.
34. Jolly SS, Shenkman H, Brieger D, et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2011;97:197-202.
35. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007;128:282-6.
36. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
37. Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomized controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190-6.
38. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210-16.
39. Wu AH, Lu QA, Todd J, et al. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009;55:52-8.
40. Frankenstein L, Wu AH, Hallermayer K, et al. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011;57:1068-71.
41. Kavsak PA, Ko DT, Wang X, et al. 2007 Universal myocardial infarction definition change criteria for risk stratification by use of a high-sensitivity cardiac troponin I assay. Clin Chem 2010;56:487-9.
42. Giannitsis E, Becker M, Kurz K, et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 2010;56:642-50.
43. Kavsak PA, Ko DT, Wang X, et al. Increasing cardiac troponin changes measured by a research high-sensitivity troponin I assay: absolute vs percentage changes and long-term outcomes in a chest pain cohort. Clin Chem 2010;56:1902-4.
44. Collinson PO, Hadcocks L, Foo Y, et al. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998;35:380-6.
45. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197-204.
46. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005;112:3088-96.
47. Hickman PE, Koerbin G, Southcott E, et al. Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease. Ann Clin Biochem 2007;44:285-9.
48. Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006;92:804-9.
49. deFilippi CR, Thorn EM, Aggarwal M, et al. Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. Am J Cardiol 2007;100:885-9.
50. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006;113:1071-8.
51. Eggers KM, Jaffe AS, Lind L, et al. Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem 2009;55:85-92.
52. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011;97:823-31.
53. Jaffe AS. The 10 commandments of troponin, with special reference to high sensitivity assays. Heart 2011;97:940-6.